Literature DB >> 21339090

[Cost of childhood asthma in Spain: a cost evaluation model based on the prevalence].

A J Blasco Bravo1, E G Pérez-Yarza, P Lázaro y de Mercado, A Bonillo Perales, C A Díaz Vazquez, A Moreno Galdó.   

Abstract

INTRODUCTION: Asthma is the most common chronic disease in childhood, reduces the quality of life of children and their families, and produces high social and health care costs. In Spain, the cost of managing paediatric asthma is unknown.
OBJECTIVE: To estimate the cost of managing paediatric asthma in Spain and to examine its variability depending on asthma severity. PATIENTS AND METHODS: The cost of asthma in children under 16 years in 2008 was estimated by building a costs assessment model including the factors that influence the cost of asthma in children: prevalence, distribution of disease severity, age, frequency of resources use depending on severity, and the cost of each resource. A sensitivity analysis was conducted to evaluate the underlying uncertainty depending on the variability of the estimators of resource use, the unit cost of each resource, and the prevalence.
RESULTS: According to the model, the total cost of paediatric asthma in Spain is around 532 million euros, with a range of 392 to 693 million euros. Direct costs (health care costs) represent 60% of the total costs, and indirect costs (carer time), 40%. The mean annual cost per child with asthma is 1,149 euros, ranging from 403 euros for the mildest category of the disease to 5,380 euros for the most severe.
CONCLUSIONS: The cost of paediatric asthma in Spain is very high and depends on disease severity. Although the most important costs are for the health care system, indirect costs are not negligible.
Copyright © 2010 Asociación Española de Pediatría. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21339090     DOI: 10.1016/j.anpedi.2010.10.006

Source DB:  PubMed          Journal:  An Pediatr (Barc)        ISSN: 1695-4033            Impact factor:   1.500


  8 in total

1.  Economic Burden of Pediatric Asthma in Turkey: A Cost of Illness Study from Payer Perspective.

Authors:  Bülent Enis Şekerel; Haluk Türktaş; Sevim Bavbek; Ergün Öksüz; Simten Malhan
Journal:  Turk Thorac J       Date:  2020-07

2.  Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.

Authors:  M Sanchez-Luna; R Burgos-Pol; I Oyagüez; J Figueras-Aloy; M Sánchez-Solís; F Martinón-Torres; X Carbonell-Estrany
Journal:  BMC Infect Dis       Date:  2017-10-17       Impact factor: 3.090

3.  Estimates of costs for modelling return on investment from smoking cessation interventions.

Authors:  Marta Trapero-Bertran; Reiner Leidl; Celia Muñoz; Puttarin Kulchaitanaroaj; Kathryn Coyle; Maximilian Präger; Judit Józwiak-Hagymásy; Kei Long Cheung; Mickael Hiligsmann; Subhash Pokhrel
Journal:  Addiction       Date:  2018-03-13       Impact factor: 6.526

4.  Cost-effectiveness of alternative smoking cessation scenarios in Spain: results from the EQUIPTMOD.

Authors:  Marta Trapero-Bertran; Celia Muñoz; Kathryn Coyle; Doug Coyle; Adam Lester-George; Reiner Leidl; Bertalan Németh; Kei-Long Cheung; Subhash Pokhrel; Ángel Lopez-Nicolás
Journal:  Addiction       Date:  2018-03-13       Impact factor: 6.526

5.  [Variability and suitability of anti-asmathic treatment in pediatric primary health care].

Authors:  Cristina Suárez-Castañón; Gracia Modroño-Riaño; Gonzalo Solís-Sánchez
Journal:  Aten Primaria       Date:  2016-11-06       Impact factor: 1.137

6.  Cost analysis of childhood asthma in Iran: A cost evaluation based on referral center data for asthma and allergies.

Authors:  Mohammad Ali Rezvanfar; Abbas Kebriaeezadeh; Mostafa Moein; Shekoufeh Nikfar; Zahra Gharibnaseri; Akbar Abdollahi-Asl
Journal:  J Res Pharm Pract       Date:  2013-10

7.  Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain.

Authors:  Ralph Schmidt; Istvan Majer; Natalia García Román; Alejandra Rivas Basterra; ElizaBeth Grubb; Constancio Medrano López
Journal:  Health Econ Rev       Date:  2017-12-19

8.  Models for estimating and projecting global, regional and national prevalence and disease burden of asthma: protocol for a systematic review.

Authors:  Mohammad Romel Bhuia; Bright I Nwaru; Christopher J Weir; Aziz Sheikh
Journal:  BMJ Open       Date:  2017-05-17       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.